Processing

Please wait...

Settings

Settings

Goto Application

1. CA2938893 - DETERMINING A NORMALIZED EXPRESSION OF ONE OR MORE S100A AND S100A9 POLYPEPTIDE EXPRESSION PRODUCTS FOR ASSESSING CHRONIC ALLOGRAFT DYSFUNCTION

Office
Canada
Application Number 2938893
Application Date 20.02.2014
Publication Number 2938893
Publication Date 28.08.2014
Publication Kind A1
IPC
C12Q 1/6809
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6809Methods for determination or identification of nucleic acids involving differential detection
G16B 25/10
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
25ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
10Gene or protein expression profiling; Expression-ratio estimation or normalisation
C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
G01N 33/48
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
CPC
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
G01N 2333/4727
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4727Calcium binding proteins, e.g. calmodulin
G01N 2333/5412
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
52Assays involving cytokines
54Interleukins [IL]
5412IL-6
G01N 2333/5428
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
52Assays involving cytokines
54Interleukins [IL]
5428IL-10
G01N 2800/245
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
24Immunology or allergic disorders
245Transplantation related diseases, e.g. graft versus host disease
G01N 2800/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
50Determining the risk of developing a disease
Applicants UNIVERSITY HEALTH NETWORK
Inventors KESHAVJEE, SHAF
LIU, MINGYAO
CYPEL, MARCELO
Priority Data 61/766,894 20.02.2013 US
Title
(EN) DETERMINING A NORMALIZED EXPRESSION OF ONE OR MORE S100A AND S100A9 POLYPEPTIDE EXPRESSION PRODUCTS FOR ASSESSING CHRONIC ALLOGRAFT DYSFUNCTION
(FR) DETERMINATION D'UNE EXPRESSION NORMALISEE D'UN OU PLUSIEURS PRODUITS D'EXPRESSION DE POLYPEPTIDES S100A ET S100A9 POUR L'EVALUATION D'UN DYSFONCTIONNEMENT CHRONIQUE DE GREFFE ALLOGENIQUE
Abstract
(EN) Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.
(FR) L'invention concerne des méthodes pour évaluer un poumon donneur pour déterminer un dysfonctionnement chronique de greffe allogénique de poumon (CALD), éventuellement le sous-type du syndrome de la bronchiolite oblitérante (BOS) ou le sous-type du syndrome restrictif (RAS) de CALD ou le risque de développer le sous-type BOS ou le sous-type RAS de CALD après la transplantation, le procédé comprenant : a. la mesure d'un niveau d'expression normalisé d'un transcrit d'ARN d'IL-6 ou un produit d'expression de celui-ci dans un échantillon du poumon donneur avant la transplantation ou d'un niveau d'expression normalisé d'une ou de plusieurs protéines S100, éventuellement S100A8 et/ou S100A9, d'un produit d'expression polypeptidique dans un échantillon du poumon donneur après la transplantation; b. l'évaluation de la probabilité que le poumon donneur développe un CALD de sous-type BOS ou un CALD de sous-type RAS après la transplantation à partir dudit niveau d'expression d'IL-6, S100, éventuellement de S100A8 et/ou ou de S100A9, le niveau d'expression d'IL-6 étant positivement corrélé avec le développement ou une probabilité accrue de développer un CALD de sous-type RAS et/ou BOS, et S100A9 étant positivement corrélé avec le développement ou une probabilité accrue de développer un CALD de sous-type RAS.
Related patent documents